Pfizer Limited (PFIZER.NS)


NSE - NSE Delayed Price. Currency in INR
1,964.35-24.35 (-1.22%)
At close: 5:59 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1,994.05
Prev Close1,988.70
Bid0.00 x
Ask1,964.35 x
Day's Range1,960.00 - 1,994.85
52wk Range1,610.10 - 2,645.00
1y Target EstN/A
Market Cap89.86B
P/E Ratio (ttm)39.47
BetaN/A
Volume8,871
Avg Vol (3m)12,852
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters6 months ago

    Indian court extends relief to pharma firms in drug ban case

    Several companies, including Indian units of Abbott Laboratories and Pfizer Inc , and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted. On Monday, judge Rajiv Sahai Endlaw moved the hearing into his chamber from a courtroom packed with lawyers and company executives. Archana Sachdeva, a lawyer representing Cipla among other firms, said he had ordered the next hearing on March 28.

  • Reuters6 months ago

    Indian court grants temporary relief to Abbott, Glenmark in drug ban case

    An Indian court on Tuesday granted interim injunction to U.S. drugmaker Abbott's India unit , and domestic companies Glenmark Pharmaceuticals and Macleods Pharmaceuticals, on the prohibition on sale of several combination drugs. The judge in the Delhi High court granted an interim stay to the pharmaceutical companies and said regulators should take "no coercive steps" against them.

  • Reuters6 months ago

    Indian court grants Pfizer temporary relief on cough syrup ban

    MUMBAI/NEW DELHI, March 14 (Reuters) - An Indian court granted U.S. drugmaker Pfizer an interim injunction on a ban on its popular cough syrup Corex, days after the government ordered it to be prohibited citing a potential risk to humans. India's health ministry banned the combination of chlorpheniramine maleate and codeine syrup, which Pfizer sells as the cough syrup Corex, in a notice over the weekend.